Evidence map›Paper›PMID 39575127›Full record

ArticleJournal of current glaucoma practice

12-month Safety and Efficacy Outcomes of a Standalone Trabecular Bypass Device.

Brandon Huynh, Colin Clement, Vuong Nguyen, Stephen O'Hagan, Frank Howes, Peter Macken, David Manning, Ridia Lim, Jed Lusthaus, Mitchell Lawlor

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of current glaucoma practice. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Brandon HuynhDepartment of Ophthalmology, Sydney Eye Hospital, Sydney, NSW, Australia.
Colin ClementGlaucoma Unit, Sydney Eye Hospital, Sydney, NSW, Australia.
Vuong NguyenDepartment of Ophthalmology Faculty of Medicine and Health, Save Sight Institute, University of Sydney, Sydney, NSW, Australia.
Stephen O'HaganDiscipline of Ophthalmology, School of Medicine, James Cook University, Cairns Hospital, Queensland, Australia.
Frank HowesDiscipline of Ophthalmology, Bond University, Queensland, Australia.
Peter MackenDiscipline of Ophthalmology, University of Wollongong, Wollongong, NSW, Australia; Department of Ophthalmology, Bowral and District Hospital, Bowral, NSW, Australia.
David ManningHunter Cataract and Eye Centre, Charlestown, NSW, Australia.
Ridia LimGlaucoma Unit, Sydney Eye Hospital, Sydney, NSW, Australia.
Jed LusthausGlaucoma Unit, Sydney Eye Hospital, Sydney, NSW, Australia; Discipline of Ophthalmology, The University of Sydney, Sydney, NSW, Australia.
Mitchell LawlorDepartment of Ophthalmology, Save Sight Institute, Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia; Glaucoma Unit, Sydney Eye Hospital, Sydney, NSW, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: To analyze the outcomes of the iStent inject in a real-world clinical setting as a standalone procedure to lower intraocular pressure (IOP) in open-angle glaucoma. Materials and methods: Patients with open-angle glaucoma having undergone iStent inject insertion without concurrent cataract extraction were included in this multicenter observational real-world study in Australia. Patient data was entered into the Fight Glaucoma Blindness! Registry. Assessments through 12 months included glaucoma subtype, IOP, medications, best-corrected visual acuity (BCVA), secondary surgical procedures, and adverse events. Kaplan-Meier survival curves for outcomes were reported according to the World Glaucoma Association (WGA). Results: Sixty-one eyes from 44 patients with a mean age of 76 ± 11.4 underwent standalone iStent inject implantation. The mean ± SD preoperative IOP was 17.5 ± 7.5 mm Hg, and the mean preoperative number of topical medications was 2.5 ± 1.5. At 12 months postoperatively, there was no statistically significant IOP reduction, while the number of glaucoma medications used was reduced to 1.4 ± 1.5 ( Conclusion: This assessment of standalone iStent inject implantation did not show any significant reduction in IOP, but there was a significant decrease in medication use in the real-world clinical setting. The procedure is safe with minimal adverse outcomes; however, a subset of patients required secondary procedures within 12 months of follow-up. How to cite this article: Huynh B, Clement C, Nguyen V,

Indexed as

GlaucomaiStent injectMinimally invasive glaucoma surgeryReal world data

Identifiers

PMID39575127
PMCPMC11576339

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.